Menopause Treatment, Reformulated Filgrastim

MenoGeniX is focused on developing MNGX-100, a biopharmaceutical product aimed at providing an alternative treatment for menopausal symptoms, particularly hot flashes and related vasomotor symptoms. This innovative approach seeks to address the unmet medical needs of women who experience moderate to severe hot flashes due to naturally occurring or surgically induced menopause. MenoGeniX's commitment to clinical research is underscored by its completion of a Phase I clinical trial, which evaluated the safety and effectiveness of MNGX-100 in a controlled setting involving 30 participants.

The company has also received funding from the National Institute on Aging (NIA) of the National Institutes of Health (NIH) to support further clinical development of MNGX-100. This funding will facilitate a Phase Ib/IIa clinical trial that aims to assess the safety and efficacy of multiple doses of the treatment in a larger cohort of 60 women. MenoGeniX's research and development efforts highlight its dedication to providing a viable alternative to existing FDA-approved hormone therapies and anti-depressants, thereby enhancing the quality of life for women experiencing menopausal symptoms.

United States

MenoGeniX is a privately-held, clinical stage biopharmaceutical company, dedicated to researching and developing a novel potential treatment for women suffering from hot flashes and related vasomotor symptoms of menopause.

MenoGeniX

Company Details